Alembic Pharmaceuticals Limited has informed the Exchange that it has received Establishment Inspection Report (EIR) for its API-III Facility at Karakhadi

Capex & Operations View source PDF Explain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹967.50

prior close

₹954.80

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.3%-0.5% vs market

Pharmaceuticals peers, median of 149sector-0.6%-0.2% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+1.1

15m

+0.8

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-0.3-0.5-0.6-0.2

Next day

-3.9-2.1-1.8-2.3-1.6

+0.2-1.8+2.0-1.5+1.6

-3.3-1.6-1.8-1.7-1.6

-2.8-1.1-1.7-1.1-1.7

+0.5+0.8-0.3-0.1+0.6

+0.6+1.4-0.8+0.1+0.5

15d

+1.8+2.5-0.7+1.1+0.7

+6.3+4.0+2.3+2.9+3.4

-0.2-0.9+0.7-2.0+1.7

-1.1+2.1-3.2+0.3-1.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alembic Pharmaceuticals has received the Establishment Inspection Report (EIR) from the US FDA for its API-III manufacturing facility at Karakhadi, Vadodara. The EIR closes out the USFDA inspection that was conducted at the facility from March 17 to March 21, 2025. Receiving an EIR indicates the inspection has been successfully closed by the regulator without any outstanding compliance concerns. The company had earlier intimated the exchanges on March 21, 2025, about the successful completion of this inspection.

Likely market impact

Positive for shareholders — the EIR confirms that the API-III facility remains compliant with USFDA standards, which is important for Alembic's US business and future product approvals/supplies from this plant. This reduces regulatory overhang and supports continuity of exports from the Karakhadi facility.